Smoke scams: attempts by obsessed controllers to impose their will on others. Regardless of the mask they wear, where they work or their educational background, their agenda is the same: making others over in their own image.

Report on Epidemiological Studies, Court Cases


Results of large study, published 2002: "We found a rather remarkably low SMR (standardized mortality ratio) for lung cancer among female cabin attendants and no increase for male cabin attendants, indicating that smoking and exposure to passive smoking may not play an important role in mortality in this group." Smoking during airplane flights was permitted in Germany until the mid-1990s and smoking is still not banned on all charter flights," stated the study, "Mortality from Cancer and Other Causes Among Airline Cabin Attendants in Germany, 1960-1997," from the Department of Epidemiology and Medical Statistics, School of Public Health, World Health Organization Collaborating Center, University Bielefeld, Germany, accepted for publication May 1, 2002, and published in the American Journal of Epidemiology. The study claimed to be the first to have reported mortality risk estimates for cabin crews working in commercial aviation. It included approximately 16,000 female and 4,500 male cabin attendants and was larger than all previous studies of cabin attendants combined. "In terms of specific causes, we noted reduced risks for all cancer deaths and for cardiovascular disease deaths."
(See abstract and full study)


Result of case study, published 2001: The ETS levels in the nonsmoking area were compared with those in similar restaurants/pubs where indoor smoking is altogether prohibited. The results indicate that ETS component concentrations in the nonsmoking section of the facility in question were not statistically different (p<0.05) from those measured in similar facilities where smoking is prohibited. The regulatory implications of these findings are that ventilation techniques for restaurants/pubs with separate smoking and nonsmoking areas are capable of achieving nonsmoking area ETS concentrations that are comparable to those of similar facilities that prohibit smoking outright," stated the study conducted in Ontario, Canada, "Environmental Tobacco Smoke in the Nonsmoking Section of a Restaurant: A Case Study," published Nov. 20, 2001, Elsevier Science.
(See full study)


"A well-known toxicological principle is that the poison is in the dose," said Roger Jenkins, Chemical and Analytical Chemistry Division, Oak Ridge National Laboratory. "It's pretty clear that the environmental tobacco smoke dose is pretty low for most people."
(See article: Just how harmful is environmental tobacco smoke? )
(See article: Exposures to second-hand smoke lower than believed, ORNL study finds)

Report: Continued


"Association is NOT causation. Relative risks are only statistical associations. They represent only an apparent relationship between exposure and disease. The relative risks of ETS and lung cancer vary from extremely weak to non-existent," stated Littlefield & Fennell, Independent Public and Health Policy Research, Austin., in "Environmental Tobacco Smoke, No Convincing Evidence of Carcinogenicity."
(See full report on at:
(Full report, Page 40)


Review: In her book, "The Truth About the Drug Companies: How They Deceive Us and What to Do About It," published by Random House in 2004, Marcia Angell, M.D., senior lecturer in the Department of Social Medicine at Harvard Medical School and former Editor-in-Chief of the New England Journal of Medicine, is quoted by reviewer John Hoey, M.D., as stating the following: Pharmaceutical Research and Manufacturers of America, the pharmaceutical industry's trade association has "the largest lobby in Washington," which in 2002 employed 675 lobbyists, including 26 former members of Congress, at a cost of more than $91 million. The result has been above average growth in corporate profits during both Republican and Democratic administrations. The most recent and perplexing lobbying effort caused Congress explicitly to prohibit Medicare from using its huge purchasing power to get lower prices for drugs, thus opening up a dollar pipeline, in the form of higher drug prices, directly from taxpayers to corporate coffers. The overall effect has been a corruption not only of science but also of the dissemination of science.

By Angell's account, the current slide toward the commercialization and corruption of clinical research coincided with the election of President Ronald Reagan in 1980 and the passage of the Bayh-Dole Act, a new set of laws that permitted and encouraged universities and small businesses to patent discoveries from research sponsored by the National Institutes of Health (NIH). Research paid for by the public to serve the public instantly became a private, and salable, good, one that is producing drug sales of more than $200 billion a year.

Angells reminds us of the increasingly cozy relationships between big industry and the facilities of universities. Not only are narcissistic donors renaming the medical schools; they are buying access to the best minds of their facilities. Angell's examples of the large consulting fees paid by industry to individual faculty members and to NIH scientists and directors are astonishing.
(See Review)

Report: Continued


In her editorial, "Is Academic Medicine For Sale?," Marcia Angell points out the increasing difficulty the New England Journal of Medicine had in finding physicians to review materials that they didn't have a vested interest in agreeing with the conclusions. She begins the editorial with the following:

"In 1984 the Journal became the first of the major medical journals to require authors of original research articles to disclose any financial ties with companies that make products discussed in papers submitted to us. (1) We were aware that such ties were becoming fairly common, and we thought it reasonable to disclose them to readers. Although we came to this issue early, no one could have foreseen at the time just how ubiquitous and manifold such financial associations would become. The article by Keller et al. (2) in this issue of the Journal provides a striking example. The authors' ties with companies that make antidepressant drugs were so extensive that it would have used too much space to disclose them fully in the Journal. We decided merely to summarize them and to provide the details on our Web site."

She goes on to say:

"In this editorial, I wish to discuss the extent to which academic medicine has become intertwined with the pharmaceutical and biotechnology industries, and the benefits and risks of this state of affairs. Bodenheimer, in his Health Policy Report elsewhere in this issue of the Journal, (5) provides a detailed view of an overlapping issue — the relations between clinical investigators and the pharmaceutical industry.

"The ties between clinical researchers and industry include not only grant support, but also a host of other financial arrangements. Researchers serve as consultants to companies whose products they are studying, join advisory boards and speakers' bureaus, enter into patent and royalty arrangements, agree to be the listed authors of articles ghostwritten by interested companies, promote drugs and devices at company-sponsored symposiums, and allow themselves to be plied with expensive gifts and trips to luxurious settings. Many also have equity interest in the companies."

Sha slso discusses the following:

"Academic medical institutions are themselves growing increasingly beholden to industry. How can they justify rigorous conflict-of-interest policies for individual researchers when their own ties are so extensive? Some academic institutions have entered into partnerships with drug companies to set up research centers and teaching programs in which students and faculty members essentially carry out industry research."
(See Angell Editorial)

Misinformation Age


Report | Report 2